#South Korea #Seoul #CAR-T therapy #Autoimmune Disease #CREATE Medicines

CREATE Medicines to Present In Vivo CAR-T Innovations at APLAR 2026

CREATE Medicines, Inc., a pioneering biotechnology company focused on in vivo multi-immune programming, will host a pivotal pre-congress workshop entitled "In Vivo CAR-T: The Next Standard of Care for Autoimmune Disease?" at the Asia-Pacific League of Associations for Rheumatology (APLAR) 2026 congress. This event will run from October 28 to November 1, 2026, at the COEX Convention Exhibition Center in Seoul, South Korea.

The workshop is designed to convene top clinicians and researchers in the fields of rheumatology and cell therapy, carefully assembled to discuss the promising potential of in vivo CAR-T therapies for treating autoimmune diseases, such as lupus and systemic sclerosis. Notable speakers at the event include Prof. Georg Schett of FAU Erlangen-Nürnberg and Prof. Cameron Turtle of The University of Sydney, both of whom have made significant contributions to the field through pioneering studies aimed at understanding and leveraging CAR-T technology in clinical applications.

Prof. Schett’s CASTLE study has been instrumental in demonstrating the efficacy of CAR-T in achieving durable, drug-free remissions, while Prof. Turtle’s research facilitated the initial clinical use of CD19 CAR-T in oncology. Their insights into the practical realities and future directions of CAR-T in autoimmune conditions will play an essential role in the discussions scheduled for the workshop.

Daniel Getts, PhD, Co-Founder and CEO of CREATE Medicines, will lead the workshop, emphasizing the transformative implications of harnessing in vivo CAR-T technology for more widespread use in clinical settings. He noted, "Our lead program, CRT-402, aims to replicate the immune-resetting properties observed with ex vivo CAR-T by programming a patient’s T cells directly within the body, allowing for effective treatment without the complexities of cell manufacturing and conditioning therapy."

On October 31, Dr. Adam Raff, SVP of Autoimmune Clinical Development at CREATE, will present critical findings from preclinical studies that showcase the success of CREATE's in vivo CAR-T approach in depleting disease-causing B cells from deep tissues. His presentation, themed "In Vivo Generation of CAR-T Cells for the Treatment of B-cell Mediated Autoimmune Disease," will underline potential breakthroughs in treating challenging autoimmune conditions.

Workshop Details

• - Title: In Vivo CAR-T The Next Standard of Care for Autoimmune Disease?
• - Date & Time: October 29, 2026, from 1500 to 1700 KST
• - Location: Room 202, Level 2, COEX Convention Exhibition Center, Seoul
• - Chair and Moderator: Daniel Getts, PhD

Program Highlights

• - Bespoke Therapy to Reproducible Medicine - Prof. Cameron Turtle, The University of Sydney
• - CAR-T at the Bedside in Autoimmunity - Prof. Georg Schett, FAU Erlangen-Nürnberg
• - Cytokine Release Syndrome Biomarkers - Prof. Shirley Chan, The University of Hong Kong
• - The Immune Reset via In Vivo CAR-T - Adam Raff, MD, PhD, CREATE Medicines
• - Panel & QA: Join a discussion on future standards of care with speakers and local experts

About CRT-402

CRT-402 stands as CREATE Medicines' flagship in vivo CAR-T candidate targeting autoimmune diseases, utilizing a cutting-edge mRNA-LNP platform for delivering precise immune modulation without the need for ex vivo manipulation. Currently being assessed in Australian clinical trials, CRT-402 is designed to allow repeated administration while facilitating deep B cell depletion, crucial for resetting the immune system.

```markdown
For more information about CREATE Medicines and their ongoing research initiatives, visit createmedicines.com.

Follow CREATE on LinkedIn, Twitter, and Bluesky for latest updates.
```

As the conversation around in vivo CAR-T therapies gains momentum, CREATE Medicines is committed to spearheading advancements that redefine treatment horizons for patients affected by autoimmune diseases, ensuring broader accessibility to innovative therapies.